Printer Friendly

Gene therapy using interleukin 12 successfully treats GVHD in mice.

Gene therapy using interleukin 12 (IL-12) is an effective treatment for graft- versus-host disease (GVHD) in mice, according to a study by Japanese researchers.

Since GVHD is characterized by the production of Th2 cytokines, and IL-12 is know to reduce TH2 activity, Tadanobu Okubo, PhD and co-investigators at Yokohama City University of Medicine in Japan theorized that gene therapy with IL-12 might affect the clinical manifestations of GVHD in mice models of the disease. The treatment groups received intramuscular injections every 3 weeks of varying doses of DNA plasmids that encode for IL-12.

The 100 mcg dose of IL-12 DNA "...prevented the development of both the immunological and clinical manifestations of chronic GVHD," Okubo and colleagues reported in the April 1 issue of the Journal of Immunology. IL-12 gene therapy also "...altered the balance between Th2 and Th1 cytokine production, suppressed hypergammaglobulinemia, and prevented the [kidney complications seen] in chronic GVHD." In contrast, the authors said administration of the plasmid encoding an IL-12 antagonist exacerbated GVHD.

The study is the first to demonstrate in an animal model that GVHD can be effectively treated with IL-12 gene therapy, and that this treatment does not induce acute GVHD, the researchers wrote. The findings, they said, support a critical role for IL-12 "...in determining the cytokine balance in GVHD," and suggest that gene therapy with IL-12 may be of benefit in a variety of human autoimmune disorders. The authors added that IL-12 gene therapy may offer significant advantages over current treatments for GVHD which rely on "...multiple daily injections of expensive cytokines."
COPYRIGHT 1999 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Gene therapy using interleukin 12 successfully treats GVHD in mice.
Publication:Transplant News
Geographic Code:9JAPA
Date:Jul 16, 1999
Words:259
Previous Article:Hepatitis C-positive livers transplanted in HCV-infected patients work well.
Next Article:Peritoneal dialysis should be used for patients waiting for kidney transplants.
Topics:


Related Articles
Bacterial decontamination reduces GVHD in patients receiving BMTs, study finds.
Neural stem cells showing promise as treatment for aggressive form of brain cancer, scientists find.
Cell Genesys issued patent for adeno-associated viral gene therapy.
AVAX receives contract from French Army to evaluate gene therapy technology.
Gene therapy in mice effective but caused serious side effects, study finds.
Gene therapy fights MD in mice.
Therapeutic cloning partially corrects immune system defect in mice.
New methods for improving mismatched BMT success rates.
Therapeutic cloning partially corrects immune system defect in mice.
AMT licenses rights on IL-10 for ex-vivo gene therapy.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters